migraine%20headache
MIGRAINE HEADACHE
Migraine headache without aura has at least 5 attacks of any 2 symptoms of unilateral headache that is throbbing or pulsating in nature, moderate to severe in pain and activity aggravates pain. It is accompanied with either nausea and vomiting or photophobia &/or phonophobia. The symptoms last for 4-72 hours without signs of secondary headache.
Migraine headache with aura has at least 2 attacks with any of the fully reversible symptoms of flickering lights, spots or lines &/or vision loss, sensory symptoms of pins & needles &/or numbness and dysphasic speech disturbance but without motor weakness. Accompanied by at least 2 of the following symptoms of homonymous visual symptoms &/or unilateral sensory symptoms or at least 1 aura symptoms develop gradually over ≥5 minutes &/or different aura symptoms that occur in succession over ≥5 minutes.

Principles of Therapy

Principles of Treatment - Acute Treatment

  • Therapy should be guided according to frequency, duration and severity of attacks, associated symptoms, degree of disability, history of treatment and patient’s preference
  • Coexisting medical conditions should also be considered in migraine therapy
    • Myocardial infarction, stroke, epilepsy, affective and anxiety disorders are common in patients with migraine
  • Effective therapy should be established and promptly used to decrease pain and disability
  • Non-oral route of administration should be used in patients who suffer migraines associated with severe nausea and vomiting
  • Antiemetics should be used if nausea and vomiting are likely to occur
  • Educate patient about avoiding medication overuse
    • Administer preventive therapy if necessary
  • To avoid headache from drug overuse, simple analgesics should be taken for a maximum duration of 15 days per month while combined analgesics should be taken up to 10 days per month

Goals of Treatment - Acute Treatment

  • Abort migraine attack
  • Treat migraine attack rapidly and consistently without recurrence
  • Restore patient’s ability to function
  • Minimize need for back-up and rescue medications
  • Self-care should be optimized
  • Avoid adverse effects

Criteria for a Successful Treatment

  • Pain-free after 2 hours
  • Improvement of migraine from moderate or severe to mild or none after 2 hours
  • Consistent efficacy in 2 of 3 migraine attacks
  • Sustained pain relief defined as absence of headache recurrence and no further intake of drugs within 24 hours

Management Strategy - Acute Treatment
Stratified Care Strategy

  • Acute treatment is based on headache severity
  • Promotes the use of migraine-specific agents for moderate to severe headache regardless of the previous response to other agents

Stepped Approach

  • Use of drugs is based on a progressive predetermined way
  • Safe, effective and inexpensive medications are used as 1st-line agents
  • If initial agent fails, migraine-specific medication is then used
  • Eg commence treatment with an analgesic with or without antiemetic, then escalating to triptan or 5HT1 receptor agonist

Principles of Therapy - Prophylactic Treatment 

  • Agent used should be started at a low dose and slowly titrated to higher doses
    • Increase dose until benefit is seen or until limited by adverse events
  • Choice of drug agent depends on the following: Adverse effects, presence of comorbidities, drug interactions, evidence-based efficacy, patient preference
  • Migraine prophylaxis is considered successful if there is at least 50% decrease in the frequency of migraine attacks per month within 3 months
  • Prophylactic drugs that are effective should be continued for 4-6 months followed by withdrawal by tapering the dose over 2-3 weeks 

Goals of Treatment - Prophylactic Treatment 

  • Reduce severity, duration and frequency of migraine headache
  • Improve patient’s quality of life and decrease disability
  • Improve response to acute therapy 
Editor's Recommendations
Most Read Articles
08 Jun 2018
High-sensitivity C-reactive protein (hs-CRP) concentration is significantly associated with long-term cognitive decline, according to a study. This suggests the possibility of CRP being a marker of cognitive decline and serving as the basis for early intervention to prevent further deterioration.
07 Jun 2018
Polypharmacy at ages 60–64 years and at age 69 years, especially in those with longstanding polypharmacy, is linked to lower physical and cognitive capability, according to a recent study.
09 Jun 2018
Dementia appears to drive hospital readmission among elderly adults, with its effect varying according to the primary diagnosis, according to a recent study.